Marta Guzman

Anti-tumor activity of the Hsp90 inhibitor IPI-504 in HER2 positive trastuzumab-resistant breast cancer.

J. Baselga, V. Serra, K. West, 2011 .

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

C. Caldas, A. Gonzalez-Perez, N. López-Bigas, 2021, Nature Communications.